Image Response Assessment Team

图像响应评估团队(IRAT)共享资源 项目总结 放射学最初是一门专门研究解剖可视化的学科。在癌症的背景下， 现代技术和创新将成像转变为一种非侵入性工具，不仅可以评估固体 肿瘤的大小和形状，但也询问肿瘤内的空间异质性的基础上 放射学外观、新陈代谢和生理学形象反应评估的总体目标 团队(IRAT)共享资源是为了提高临床研究的科学质量，通过提供单点 Moffitt癌症中心(MCC)成员访问传统和高级定量图像的入口 分析服务。为此，围绕三个具体目标组织了努力，即：1)维持和 提高RECIST的高可靠性和快速周转时间(Solid中的响应评估标准 肿瘤)和其他标准的肿瘤评估指标；2)通过翻译改进MCC的治疗试验 放射组学和多参数磁共振(MpMRI)分析成为交钥匙成像生物标志物的研究进展 服务；以及3)为成员提供用于治疗试验的非传统成像终端。IRAT 由五名全职工作人员组成，提供基于图像的定量肿瘤指标，以支持研究人员- 在MCC发起、合作小组和行业赞助的临床试验，是国家 癌症中心IRATs联盟。IRAT在MCC使命中扮演着至关重要的角色 通过提供必要的支持和服务，将传统的 和创新的成像终端进入临床试验，并在整个过程中提供质量保证和控制 产生科学有效结果的过程。随着治疗范例的快速发展，例如 免疫疗法，IRAT提供了改进的成像终点，以满足这些前沿研究的需求 MCC成员的数量。IRAT的定量图像响应量持续增加 提供评估服务。总共启动了298项需要成像反应评估的新试验 在2011-2015财年，从2011财年的39人上升到2015财年的65人。为iRAT开发基础设施允许 寻求使用先进和/或探索性成像技术的其他资助试验机会， 分析，和新的生物标志物。例如，iRAT正在支持多种赠款申请，并得到资助 研究放射学和mpMRI成像生物标志物的成员项目的回顾和展望 临床和临床前研究。在过去的项目期间，IRAT为来自4个MCC的34名成员提供了服务 程序。会员的总使用率为94%，其中63%的总使用量支持具有对等- 审查了资金来源。期间，由IRAT支持的研究共发表了62篇同行评审的科学出版物 这段时间。

Image Response Assessment Team (IRAT) Shared Resource PROJECT SUMMARY Radiology began as a discipline that specialized in the visualization of anatomy. In the context of cancer, modern technologies and innovations transformed imaging into a non-invasive tool that not only assesses solid tumor size and shape but also interrogates the spatial heterogeneity within tumors on the basis of their radiologic appearance, metabolism, and physiology. The overall goal of the Image Response Assessment Team (IRAT) Shared Resource is to enhance the scientific quality of clinical studies, by offering a single point of entry for Moffitt Cancer Center (MCC) members to access traditional and advanced quantitative image analysis services. To this end, efforts are organized around three Specific Aims, which are to: 1) maintain and improve the high reliability and fast turnaround times for RECIST (Response Evaluation Criteria in Solid Tumors) and other standard tumor assessment metrics; 2) improve therapeutic trials at MCC by translating research advances in radiomics and multi-parameter MRI (mpMRI) analyses into turnkey imaging biomarker services; and 3) provide members with access to non-traditional imaging endpoints for therapeutic trials. IRAT consists of five full-time staff and provides quantitative image-based tumor metrics to support investigator- initiated, cooperative group, and industry-sponsored clinical trials at MCC, and is part of the national consortium of Cancer Center IRATs. IRAT has essential roles in the MCC mission “to contribute to the prevention and cure of cancer,” by providing the support and services necessary to integrate both traditional and innovative imaging endpoints into clinical trials and by providing quality assurance and control throughout the process to yield scientifically valid results. With rapid advances in treatment paradigms such as immunotherapies, IRAT provides improved imaging endpoints to meet the needs of these cutting-edge studies of MCC members. IRAT has witnessed sustained increases in the volume of quantitative image response assessment services provided. A total of 298 new trials requiring imaging response assessment were activated in FY11-15, rising from 39 in FY11 to 65 in FY15. Developing an infrastructure for IRAT has permitted the pursuit of other funded trial opportunities that use advanced and/or investigational imaging techniques, analyses, and novel biomarkers. For example, IRAT is supporting multiple grant applications and funded projects by members investigating radiomic and mpMRI imaging biomarkers in retrospective and prospective clinical and pre-clinical studies. During the past project period, IRAT served 34 members from 4 MCC Programs. Overall usage by members was 94%, with 63% of total usage supporting members with peer- reviewed funding. IRAT-supported studies resulted in a total of 62 peer-reviewed scientific publications during this period.